BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical
management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the …

The management of hematologic malignancies, including chronic myeloid leukemia (CML),
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …

Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The
Paradigm for Monitoring Targeted Cancer Therapy | The Oncologist | Oxford Academic Skip to …

Relapse of chronic myelogenous leukemia after bone marrow transplantation can be
detected by using clinical, cytogenetic, or molecular tools. A modification of the polymerase …

For the great majority of patients with chronic myeloid leukaemia (CML), the Philadelphia
(Ph) chromosome is a specific marker of the malignant clone. The standard method to …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

In patients with chronic myeloid leukemia, the use of real-time quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) for measuring BCR-ABL1 transcripts …

Real-time RT-PCR has great advantages for estimating transcript levels in a variety of
situations. These include relative rapid assay times (hours), reliability and ease of …

Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep
molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a
triphasic clinical course, the morphologic expansion of a terminally differentiated myeloid …